Acp-204 Tartrate — Drug Intelligence | 4 EU Trials

Filter these 4 trials by condition, phase, country and more.

4 Registered trials

3 Recruiting

1 Completed trials

1 Sponsors

5 Countries

Phase III

Phase II

Phase III: 2 Phase II: 2

Indications tested

4 total

ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521711-39-00 Phase III 4 countries Acadia Pharmaceuticals Inc.
ACP-204 in Adults With Lewy Body Dementia Psychosis (LBDP) Recruiting

2025-521710-25-00 Phase II 4 countries Acadia Pharmaceuticals Inc.
This 52-week, open-label extension study is to evaluate the long-term safety and tolerability of ACP-204 in subjects with ADP. Recruiting

2023-507351-29-00 Phase III 5 countries Acadia Pharmaceuticals Inc.
ACP-204 in Adults with Alzheimer’s Disease Psychosis Ended

2023-507325-42-00 Phase II 5 countries Acadia Pharmaceuticals Inc.

Showing 1–4 of 4 trials